Market Place
Sourcing Support
Neurosigma Invests $1M In Manufacturing For Monarch eTNS Device
15 Dec 2025 //
GLOBENEWSWIRE
NeuroSigma Launches Monarch for Pediatric ADHD After Pilot Study
18 Nov 2025 //
GLOBENEWSWIRE
Neurosigma Reveals Real-Time Brain Activity Effects Of eTNS
03 Nov 2025 //
GLOBENEWSWIRE
NeuroSigma Gets Patent Allowance for Monarch eTNS System in China
10 Jun 2025 //
GLOBENEWSWIRE
NeuroSigma Announces New Clinical Trial of Monarch eTNS System
30 Apr 2025 //
GLOBENEWSWIRE
NeuroSigma Patent Protects Trigeminal Nerve Use For Dyslexia
22 Jan 2025 //
GLOBENEWSWIRE
Monarch eTNS ADHD Trial At King’s College Completes Enrollment
13 Jan 2025 //
GLOBENEWSWIRE
New Pediatric ADHD eTNS Trial to Start at Denmark’s Center
11 Dec 2024 //
GLOBENEWSWIRE
NeuroSigma In 2024 KidsX Accelerator Program Cohort
09 May 2024 //
GLOBENEWSWIRE
NeuroSigma Announces FDA Clearance of its Monarch eTNS System
18 Jan 2024 //
GLOBENEWSWIRE
NeuroSigma Announces FDA Submission for Second Generation Monarch eTNS System
07 Nov 2023 //
GLOBENEWSWIRE
NeuroSigma Announces HSA Approval of the Monarch eTNS System in Singapore
03 Oct 2023 //
GLOBENEWSWIRE
NeuroSigma Establishes Singapore Subsidiary
12 Jul 2023 //
GLOBENEWSWIRE
NeuroSigma Announces New Telehealth Option for Patients eTNS for Pediatric ADHD
01 Mar 2023 //
GLOBENEWSWIRE
NeuroSigma Announces Strategic Digital Marketing Partnership with Data360
31 Jan 2023 //
GLOBENEWSWIRE
NeuroSigma Announces that Enrollment Commences in Two Large,
08 Nov 2022 //
GLOBENEWSWIRE
NeuroSigma Announces Commercial Launch of The Monarch eTNS® System
17 Oct 2022 //
GLOBENEWSWIRE
NeuroSigma Announces Receipt of Permanent HCPCS Codes from CMS
27 Sep 2022 //
GLOBENEWSWIRE
UCLA Researchers Receive NIH Grant to Conduct Multicenter Trial of eTNS
14 Jun 2022 //
GLOBENEWSWIRE
King`s College London Receives MHRA Approval to Commence Largest Trial of eTNS
07 Apr 2022 //
GLOBENEWSWIRE
NeuroSigma Receives FDA Breakthrough Device Designation for Monarch eTNS System®
22 Feb 2022 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.